Methylergobrevin (Methylergobrevin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceMethylergometrineMethylergometrine
Similar drugsTo uncover
  • Methylergobrevin
    solution w / m in / in 
    Hemofarm AD     Serbia
    • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    1 ml of the solution contains active substance: methylergometrine maleate - 0.2 mg; Excipients: maleic acid 0.1 mg, glycine 0.2 mg, sodium chloride 9.0 mg, thiocarbamide 0.5 mg, water for injection up to 1.0 ml.

    Description:

    A clear, colorless solution.

    Pharmacotherapeutic group:Uterotonizing agent
    ATX: & nbsp

    G.02.A.B   Preparations of ergot alkaloids

    G.02.A.B.01   Methylergometrine

    Pharmacodynamics:

    Semisynthetic derivative of natural ergot alkaloid (ergometrine). Increases the tone and contractile activity of the myometrium. Has a weak effect on peripheral vessels, almost does not increase blood pressure.

    Pharmacokinetics:Therapeutic effect after intravenous (IV) administration is manifested in 30-60 seconds, after intramuscular (IM) administration - after 2-5 minutes. The action of the drug lasts 3 or more hours after the / m application and up to 2 hours after intravenous administration. The association of the drug with plasma proteins is 35%. The volume of distribution is 39.1-73.1 liters, the clearance is 9.9-18.9 liters / hour. The drug is quickly distributed to the tissues of the body - the half-distribution period after intravenous administration is 1-3 minutes. Penetrates into breast milk.Metabolized in the liver, excreted mainly with feces, in part - kidneys.
    Indications:

    In order to reduce the second period of labor after the appearance of the front part of the fetal arm. Childbirth (II period, after the appearance of the anterior part of the shoulder), metrorrhagia (including atonic), hypotonic bleeding in the early postpartum period (prevention and treatment), postoperative (caesarean section, removal of fibroids), postabortion.

    Contraindications:

    Pregnancy, the first period of childbirth, the second period before the appearance of the fetal head, severe forms of arterial hypertension, occlusive diseases of peripheral vessels, increased sensitivity to ergot preparations, sepsis.

    Carefully:Renal or hepatic insufficiency, cardiovascular diseases, the need for manual removal of the placenta.
    Pregnancy and lactation:

    Application during pregnancy, during lactation is contraindicated.

    Dosing and Administration:

    The dose of Methylergobrevin is determined according to the indications.

    Atonic uterine bleeding. Assign 0.1 mg (0.5 ml) IV or 0.2 mg (1 ml) IM, if necessary, the injection can be repeated at intervals of 2 hours.

    Metrorrhagia. Assign 0.1 - 0.2 mg IM or 0.1 mg IV.

    Cesarean section. The drug is administered after fetal extraction: iv in 0.05-0.1 mg or IM in 0.2 mg.

    Abortion. Assign after the dilatation of the cervical canal in / in 0,1-0,2 mg. With spontaneous abortion is shown in / in the administration of 0.05-0.1 mg.

    Childbirth. With close supervision of the obstetrician, to reduce the second period of labor, I / O, 0.1-0.2 mg of Methylergobrevin is administered only after the appearance of the head or anterior part of the fetal arm.

    When administering labor during general anesthesia, the administration of 0.2 mg-Methylergobrevin is recommended. If it is impossible to / in the use of the drug, then it is administered in / m in a dose of 0.2-0.4 mg.
    Side effects:Abdominal pain, nausea, vomiting, increased sweating, dizziness, headache, tinnitus, bradycardia, transient increase in arterial pressure, peripheral vasospasm, chest pain, dyspnoea, stroke, myocardial infarction, pulmonary edema, allergic reactions in the form of skin rash , extremely rarely-anafilactic shock, a decrease in milk secretion.
    Overdose:

    Symptoms of overdose are: nausea, vomiting, abdominal pain, sensation of numbness and tingling in the limbs, hypertension, accompanied in severe cases by respiratory depression, hypothermia, convulsions and coma.

    In case of overdose, symptomatic treatment is carried out with careful monitoring of the functions of the cardiovascular and respiratory systems.

    Interaction:

    In the treatment and prevention of atonic uterine bleeding is an effective combination of Methylergobrevin and oxytocin. Methylergobrevin may enhance the vasopressor effects of sympathomimetics and ergotamine. Combination with dopamine is contraindicated. possibly development of gangrene of extremities. Fluorotane reduces the sensitivity of the uterus and reduces the activity of metargergometrin.

    Special instructions:

    The drug should be used only in a specialized hospital, with strict medical control of blood pressure, heart rate, contractile activity of the uterus. When applied immediately after the birth of the child (if the placenta is in the uterine cavity) may interfere with the separation of the afterbirth.

    Form release / dosage:

    Solution for intravenous and intramuscular injection 200 μg / ml.

    Packaging:1 ml of the drug in a vial of colorless glass I hydrolytic class. On the ampoule are painted: with a brown paint - the first ring, with a yellow paint - the second ring and a dot.5 ampoules per contour mesh PVC-package with aluminum coating. 10 contour packs together with instructions for use in a cardboard pack.
    Storage conditions:

    At a temperature below 25 ° C in a pack of cardboard in a place protected from light.

    Keep out of the reach of children!

    Shelf life:

    3 years.

    Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:П N012451 / 01
    Date of registration:06.09.2011
    Expiration Date:Unlimited
    The owner of the registration certificate:Hemofarm ADHemofarm AD Serbia
    Manufacturer: & nbsp
    Representation: & nbspHEMOFARM A.D. HEMOFARM A.D. Serbia
    Information update date: & nbsp08.05.2018
    Illustrated instructions
      Instructions
      Up